Topics

Visen Pharma Approved for China Phase III Trial of Growth Hormone Drug

21:24 EDT 28 Oct 2019 | ChinaBio Today

Visen Pharma of Shanghai reported that China approved its IND to start a Phase III trial for TransCon human growth hormone in patients with childhood growth hormone deficiency (GHD). Visen was formed last year by Sweden's Ascendis Pharma and an investor syndicate that provided $40 million in capital, led by Vivo Capital. The company will develop Ascendis' portfolio of three endocrinology rare disease therapies in Greater China. Visen believes TransCon hGH, a long-acting drug that offers once-weekly dosing, will be the first long-acting growth hormone therapy available in China. More details....

Share this with colleagues:

Original Article: Visen Pharma Approved for China Phase III Trial of Growth Hormone Drug

NEXT ARTICLE

More From BioPortfolio on "Visen Pharma Approved for China Phase III Trial of Growth Hormone Drug"

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Endocrinology
Diabetes Diabetes Endocrine Disorders Obesity Oxycontin Renal Disease Thyroid Disorders Endocrinology is the study of the endocrine glands and the hormones that they secrete (Oxford Medical Dictionary). There are several g...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...